These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27379943)

  • 41. Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007.
    Wilcken N; Dear R
    Eur J Cancer; 2008 Oct; 44(15):2218-25. PubMed ID: 18722111
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primum non nocere.
    Templeton AJ; Šeruga B
    Ann Oncol; 2015 Oct; 26(10):2197-8. PubMed ID: 26169770
    [No Abstract]   [Full Text] [Related]  

  • 44. [New data concerning breast carcinoma. A report on the 34th Meeting of the American Society of Clinical Oncology, Los Angeles, Calif., USA, May 16-19, 1998].
    Gerber B; Krause A
    Gynakol Geburtshilfliche Rundsch; 1999; 39(3):136-9. PubMed ID: 10420058
    [No Abstract]   [Full Text] [Related]  

  • 45. Development of cell-cycle checkpoint therapy for solid tumors.
    Tamura K
    Jpn J Clin Oncol; 2015 Dec; 45(12):1097-102. PubMed ID: 26486823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized clinical trials in breast cancer: a tabular summary. Part 1: Primary breast cancer.
    Conrad B; Kieser R
    Arch Geschwulstforsch; 1986; 56(3):211-36. PubMed ID: 3524501
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eribulin in advanced breast cancer: safety, efficacy and new perspectives.
    Garrone O; Miraglio E; Vandone AM; Vanella P; Lingua D; Merlano MC
    Future Oncol; 2017 Dec; 13(30):2759-2769. PubMed ID: 29219017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Principles of adjuvant drug therapy in breast cancer].
    Castiglione M; Schnürch HG; Bender HG; Goldhirsch A
    Gynakologe; 1994 Apr; 27(2):49-63. PubMed ID: 8039743
    [No Abstract]   [Full Text] [Related]  

  • 49. Advances in the treatment of breast cancer.
    Moulder S; Hortobagyi GN
    Clin Pharmacol Ther; 2008 Jan; 83(1):26-36. PubMed ID: 18091763
    [TBL] [Abstract][Full Text] [Related]  

  • 50. American Society of Clinical Oncology Annual Meeting 2013.
    Yaqub F
    Lancet Respir Med; 2013 Jul; 1(5):360-1. PubMed ID: 24429195
    [No Abstract]   [Full Text] [Related]  

  • 51. Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials.
    Mackey JR; Kerbel RS; Gelmon KA; McLeod DM; Chia SK; Rayson D; Verma S; Collins LL; Paterson AH; Robidoux A; Pritchard KI
    Cancer Treat Rev; 2012 Oct; 38(6):673-88. PubMed ID: 22365657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ten years of HER2-directed therapy: still questions after all these years.
    Krop IE; Winer EP
    Breast Cancer Res Treat; 2009 Jan; 113(2):207-9. PubMed ID: 18463974
    [No Abstract]   [Full Text] [Related]  

  • 53. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
    Thill M
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Shah AN; Cristofanilli M
    Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current topics in breast cancer for oncology nurses.
    ONS News; 2004; 19(9 Suppl):37-8. PubMed ID: 15478579
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Introduction and commentary: paving the way for biosimilars in oncology, part 2: focus on safety and clinical trial considerations.
    Abraham J
    Semin Oncol; 2014 Feb; 41 Suppl 1():S1-2. PubMed ID: 24560023
    [No Abstract]   [Full Text] [Related]  

  • 58. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Diagnostic and therapeutic strategy in breast cancer].
    Fabrégas B
    Soins; 2003 Mar; (673):26-31. PubMed ID: 12677919
    [No Abstract]   [Full Text] [Related]  

  • 60. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
    Ogura M; Coiffier B; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.